{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:27:11Z","timestamp":1790227631085,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.bioactmat.2022.08.006","type":"journal-article","created":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T05:49:44Z","timestamp":1663480184000},"page":"483-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["HDAC I\/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells"],"prefix":"10.1016","volume":"21","author":[{"given":"Qiang","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zejiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huandi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-2140","authenticated-orcid":false,"given":"Yiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.bioactmat.2022.08.006_bib1","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1158\/1078-0432.CCR-19-0516","article-title":"Purinostat mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia","volume":"25","author":"Yang","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bioactmat.2022.08.006_bib2","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1021\/acs.jmedchem.6b00579","article-title":"Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities","volume":"59","author":"Chen","year":"2016","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioactmat.2022.08.006_bib3","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"issue":"2 Suppl 2","key":"10.1016\/j.bioactmat.2022.08.006_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin. Hematol."},{"issue":"14","key":"10.1016\/j.bioactmat.2022.08.006_bib5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bioactmat.2022.08.006_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bioactmat.2022.08.006_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12234","article-title":"Do we need more drugs for chronic myeloid leukemia?","volume":"263","author":"Holyoake","year":"2015","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.bioactmat.2022.08.006_bib8","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bioactmat.2022.08.006_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.trecan.2018.04.007","article-title":"Epigenetic priming in cancer initiation","volume":"4","author":"Vicente-Duenas","year":"2018","journal-title":"Trends in cancer"},{"issue":"6","key":"10.1016\/j.bioactmat.2022.08.006_bib10","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Holtz","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bioactmat.2022.08.006_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2017.07.006","article-title":"Epigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic options","volume":"51","author":"Koschmieder","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.bioactmat.2022.08.006_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bioactmat.2022.08.006_bib13","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","article-title":"Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3","volume":"105","author":"George","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bioactmat.2022.08.006_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bioactmat.2022.08.006_bib15","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/embor.2009.88","article-title":"Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes","volume":"10","author":"Nebbioso","year":"2009","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.bioactmat.2022.08.006_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbagrm.2017.12.002","article-title":"HDAC11 is a regulator of diverse immune functions","volume":"1861","author":"Yanginlar","year":"2018","journal-title":"Biochimica et Biophysica Acta. Gene. Regular Mech."},{"key":"10.1016\/j.bioactmat.2022.08.006_bib17","first-page":"84","article-title":"Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am Health Drug. Benefit."},{"issue":"8","key":"10.1016\/j.bioactmat.2022.08.006_bib18","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1535-7163.MCT-13-0963","article-title":"Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia","volume":"13","author":"Guzman","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.bioactmat.2022.08.006_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.stem.2015.08.004","article-title":"HDAC8 inhibition specifically targets inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation","volume":"17","author":"Qi","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.bioactmat.2022.08.006_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"6468","key":"10.1016\/j.bioactmat.2022.08.006_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bioactmat.2022.08.006_bib22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J. Exp. Med."},{"issue":"45","key":"10.1016\/j.bioactmat.2022.08.006_bib23","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.bioactmat.2022.08.006_bib24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bioactmat.2022.08.006_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.bioactmat.2022.08.006_bib26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.bioactmat.2022.08.006_bib27","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1172\/JCI66129","article-title":"Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival","volume":"124","author":"Chen","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bioactmat.2022.08.006_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bioactmat.2022.08.006_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/07853890.2022.2045347","article-title":"Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model","volume":"54","author":"Zhu","year":"2022","journal-title":"Ann. Med."},{"issue":"26","key":"10.1016\/j.bioactmat.2022.08.006_bib30","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1073\/pnas.0503280102","article-title":"Cell intrinsic alterations underlie hematopoietic stem cell aging","volume":"102","author":"Rossi","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bioactmat.2022.08.006_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","article-title":"Glutaminolysis: a hallmark of cancer metabolism","volume":"19","author":"Yang","year":"2017","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.bioactmat.2022.08.006_bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s42255-019-0039-6","article-title":"Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression","volume":"1","author":"Ni","year":"2019","journal-title":"Nature Metabolism"},{"issue":"4","key":"10.1016\/j.bioactmat.2022.08.006_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153226","article-title":"Hypoxia-Like signatures induced by BCR-ABL potentially alter the glutamine uptake for maintaining oxidative phosphorylation","volume":"11","author":"Sontakke","year":"2016","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.bioactmat.2022.08.006_bib34","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells, Clinical cancer research : an","volume":"10","author":"Gottschalk","year":"2004","journal-title":"official journal of the American Association for Cancer Research"},{"issue":"5","key":"10.1016\/j.bioactmat.2022.08.006_bib35","first-page":"1039","article-title":"Survival regulation of leukemia stem cells, Cellular and molecular life sciences","volume":"73","author":"Hu","year":"2016","journal-title":"CM"},{"issue":"8","key":"10.1016\/j.bioactmat.2022.08.006_bib36","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","article-title":"BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","volume":"68","author":"Stoklosa","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bioactmat.2022.08.006_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bioactmat.2022.08.006_bib38","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2013.092007","article-title":"Epigenetics in the hematologic malignancies","volume":"99","author":"Fong","year":"2014","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bioactmat.2022.08.006_bib39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.bbadis.2013.04.005","article-title":"Lysine deacetylases and mitochondrial dynamics in neurodegeneration","volume":"1832","author":"Guedes-Dias","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.bioactmat.2022.08.006_bib40","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2022.08.006_bib41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.carbpol.2013.09.035","article-title":"Inclusion complex of barbigerone with hydroxypropyl-beta-cyclodextrin: preparation and in vitro evaluation","volume":"101","author":"Qiu","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bioactmat.2022.08.006_bib42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.carbpol.2019.04.024","article-title":"Biotin and arginine modified hydroxypropyl-beta-cyclodextrin nanoparticles as novel drug delivery systems for paclitaxel","volume":"216","author":"Yan","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bioactmat.2022.08.006_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106078","article-title":"Improving the solubility of vorinostat using cyclodextrin inclusion complexes: the physicochemical characteristics, corneal permeability and ocular pharmacokinetics of the drug after topical application","volume":"168","author":"Yang","year":"2022","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"18","key":"10.1016\/j.bioactmat.2022.08.006_bib44","doi-asserted-by":"crossref","first-page":"20960","DOI":"10.1021\/acsami.0c22587","article-title":"Beta-cyclodextrin-poly (beta-Amino ester) nanoparticles are a generalizable strategy for high loading and sustained release of HDAC inhibitors","volume":"13","author":"Chaudhuri","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"9","key":"10.1016\/j.bioactmat.2022.08.006_bib45","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3324\/haematol.2012.080424","article-title":"Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis","volume":"98","author":"Guo","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bioactmat.2022.08.006_bib46","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1038\/cddis.2013.309","article-title":"PI3K\/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor","volume":"4","author":"Airiau","year":"2013","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.bioactmat.2022.08.006_bib47","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bioactmat.2022.08.006_bib48","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/onc.2015.174","article-title":"Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets","volume":"35","author":"Collins","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bioactmat.2022.08.006_bib49","article-title":"Emerging roles of MTG16 in cell-fate control of hematopoietic stem cells and cancer","volume":"2017","author":"Steinauer","year":"2017","journal-title":"Stem Cell. Int."},{"issue":"7","key":"10.1016\/j.bioactmat.2022.08.006_bib50","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/s41375-020-01097-x","article-title":"HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia","volume":"35","author":"De Barrios","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bioactmat.2022.08.006_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080798","article-title":"Metabolic dysregulations and epigenetics: a bidirectional interplay that drives tumor progression","volume":"8","author":"Crispo","year":"2019","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bioactmat.2022.08.006_bib52","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"issue":"6526","key":"10.1016\/j.bioactmat.2022.08.006_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1126\/science.abb5916","article-title":"Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders","volume":"371","author":"Johmura","year":"2021","journal-title":"Science"}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X2200336X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X2200336X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:36:07Z","timestamp":1762785367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X2200336X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":53,"alternative-id":["S2452199X2200336X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2022.08.006","relation":{},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC I\/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2022.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}